ASX:BD1

Stock Analysis Report

BARD1 Life Sciences

Executive Summary

BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has BARD1 Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

15.6%

BD1

1.7%

AU Healthcare

0.4%

AU Market


1 Year Return

271.4%

BD1

17.9%

AU Healthcare

9.8%

AU Market

Return vs Industry: BD1 exceeded the Australian Healthcare industry which returned 17.9% over the past year.

Return vs Market: BD1 exceeded the Australian Market which returned 9.8% over the past year.


Shareholder returns

BD1IndustryMarket
7 Day15.6%1.7%0.4%
30 Day52.9%3.6%-1.3%
90 Day44.4%1.0%-0.5%
1 Year282.9%271.4%21.6%17.9%16.1%9.8%
3 Year53.1%48.6%7.1%-2.8%36.1%17.9%
5 Yearn/a43.2%23.1%49.4%15.7%

Price Volatility Vs. Market

How volatile is BARD1 Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BARD1 Life Sciences undervalued compared to its fair value and its price relative to the market?

9.06x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BD1 is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: BD1 is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BD1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BD1 is overvalued based on its PB Ratio (9.1x) compared to the AU Healthcare industry average (1.5x).


Next Steps

Future Growth

How is BARD1 Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

9.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BARD1 Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BARD1 Life Sciences performed over the past 5 years?

-6.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BD1 is unprofitable, and losses have increased over the past 5 years at a rate of -6.5% per year.

Accelerating Growth: Unable to compare BD1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BD1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-1.7%).


Return on Equity

High ROE: BD1 has a negative Return on Equity (-24.07%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: BD1 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BD1 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is BARD1 Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: BD1's short term assets (A$7.6M) exceeds its short term liabilities (A$463.2K)

Long Term Liabilities: BD1's short term assets (7.6M) exceeds its long term liabilities (28.7K)


Debt to Equity History and Analysis

Debt Level: BD1 is debt free.

Reducing Debt: BD1 had no debt 5 years ago.


Balance Sheet

Inventory Level: BD1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BD1's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BD1 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BD1 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -13.3% each year


Next Steps

Dividend

What is BARD1 Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage2.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BD1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BD1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BD1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BD1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BD1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of BARD1 Life Sciences's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average board tenure


CEO

Leearne Hinch 0

2.9yrs

Tenure

AU$442,442

Compensation

Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of BARD1 Life Sciences Limited since November 7, 2016. Dr. Hinch is a biotechnology executive and consultant ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Leearne's total compensation is reasonable compared to companies of similar size in the Australian market.

Compensation vs Earnings: Leearne's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

2.3yrs

Average Tenure

Experienced Board: BD1's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyAU$99,99615 Jul 19
Robert Johnston
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares5,000,000
Max PriceAU$0.02
BuyAU$99,99615 Jul 19
Philip Powell
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares5,000,000
Max PriceAU$0.02
BuyAU$2,386,12119 Jun 19
Merchant Funds Management Pty Ltd
EntityCompany
Shares119,349,963
Max PriceAU$0.022
SellAU$474,97019 Jun 19
Merchant Funds Management Pty Ltd
EntityCompany
Shares23,909,752
Max PriceAU$0.02
BuyAU$1,849,95719 Jun 19
Jeffrey Emmanuel
EntityIndividual
Shares92,500,000
Max PriceAU$0.02
BuyAU$1,369,96819 Jun 19
David Williams
EntityIndividual
Shares68,500,000
Max PriceAU$0.02
SellAU$204,97902 Dec 18
Irmgard Irminger-Finger
EntityIndividual
Role
Member of the Board of Directors
Founder
Shares8,599,683
Max PriceAU$0.024
BuyAU$279,40931 Oct 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares5,105,070
Max PriceAU$0.057
SellAU$664,36331 Oct 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares16,222,101
Max PriceAU$0.058
BuyAU$263,58529 Oct 18
Credit Suisse, Investment Banking and Securities Investments
EntityCompany
Shares9,390,584
Max PriceAU$0.031

Ownership Breakdown


Management Team

  • Peter Gunzburg (67yo)

    Executive Chairman & MD

    • Tenure: 18.1yrs
    • Compensation: AU$75.28k
  • Leearne Hinch

    Chief Executive Officer

    • Tenure: 2.9yrs
    • Compensation: AU$442.44k
  • Pauline Collinson

    Company Secretary

    • Tenure: 17.9yrs
    • Compensation: AU$129.08k
  • Irmgard Irminger-Finger

    Founder

    • Tenure: 9yrs
    • Compensation: AU$150.00k

Board Members

  • Peter Gunzburg (67yo)

    Executive Chairman & MD

    • Tenure: 18.1yrs
    • Compensation: AU$75.28k
  • Philip Powell (62yo)

    Independent Non-Executive Director

    • Tenure: 0.3yrs
    • Compensation: AU$2.14k
  • Max Johnston

    Independent Non-Executive Director

    • Tenure: 0.3yrs
    • Compensation: AU$2.14k
  • Irmgard Irminger-Finger

    Founder

    • Tenure: 9yrs
    • Compensation: AU$150.00k
  • Samuel Janes

    Member of Advisory Board

    • Tenure: 2.3yrs

Company Information

BARD1 Life Sciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BARD1 Life Sciences Limited
  • Ticker: BD1
  • Exchange: ASX
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$71.094m
  • Shares outstanding: 1.37b
  • Website: https://www.bard1.com

Location

  • BARD1 Life Sciences Limited
  • Tempo Building
  • Unit B1
  • Subiaco
  • Western Australia
  • 6008
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BD1ASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2016
EGQDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2016
BD1CHIA (Chi-X Australia)YesOrdinary SharesAUAUDJun 2016

Biography

BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a screening test fo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 10:38
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.